Some regulators, including the FDA, have a 50 percent efficacy threshold for emergency approval. CureVac is moving forward with its vaccine, though, and has highlighted its data showing the vaccine’s 53 percent efficacy rate in people ages 18-60. In that group, the vaccine protected against all hospitalization and death caused by COVID-19, and it provided 77 percent protection against moderate and severe COVID-19.
The vaccine uses mRNA technology like the vaccines produced by Pfizer and Moderna, but its storage requirements are easier to meet than the ultra-cold temperatures those two already-approved vaccines require.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
